Influence of Hydrophobic Ion Pairing on Formulation Performance of Liraglutide in PLGA Microspheres.
AAPS PharmSciTech · 2025
Last updated 2026-05-28Researchers developed a new method to create long-lasting injections of liraglutide, a diabetes medication, using tiny PLGA spheres. The new approach improved how much drug was trapped inside the spheres (from 56.15% to 85.45%) and reduced the initial rapid release of the drug to just 3.58%. The spheres were about 44 micrometers wide and released the drug steadily for over 55 days.
AI summary of the abstract below.
| Journal | AAPS PharmSciTech, 2025 |
|---|---|
| Citations | 0 |
| Molecules | liraglutide |
| Conditions studied | Type 2 Diabetes, Obesity |
Abstract
The Food and Drug Administration of the United States (USFDA) and the European Medicines Agency (EMA) have approved peptide-based long-acting formulations to manage chronic diseases. However, the formulation of long-acting injectables for hydrophilic drug molecules and peptides remains a persistent challenge due to poor encapsulation and high initial burst release, which increases the complexity of the formulation. In the present research, we formulated long-acting injectable microspheres for liraglutide, a peptide used for managing type 2 DM (Diabetes Mellitus), utilizing a modified solid-oil-water (S/O/W) method. The method includes a hydrophobic ion pairing (HIP) strategy to improve the hydrophobicity of native molecules using various hydrophobic ion-pairing agents. Further, the PLGA microspheres prepared by the modified S/O/W method were compared with the traditional water-oil-water (W/O/W) double emulsion method. The modified S/O/W method (batch F2) demonstrated a significant improvement in encapsulation efficiency, increasing from 56.15% to 85.45%, and a minimal burst release of 3.58%. A comprehensive characterization of microspheres was performed using modern analytical techniques. The developed microspheres were spherical with a mean particle size of 43.97 µm and exhibited sustained drug release over 55 days. The S/O/W method demonstrated a promising approach for the encapsulation of hydrophilic peptide molecules.
Verbatim abstract via PubMed 40730914 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.